Tiziana announces positive data on intranasal anti-cd3 monoclonal antibody in intracerebral hemorrhage

New york, april 04, 2023 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced pre-clinical data on the effects of intranasal anti-cd3 monoclonal antibody in a model of intracerebral hemorrhage (hemorrhagic stroke) demonstrating a behavioral outcome improvement at one month.
TLSA Ratings Summary
TLSA Quant Ranking